부산대학교 도서관

Clinical investigations were done on the antigenicity of enramycin collaborately in 19 research organizations. Attention was given to the intracutaneous reaction, antibody in blood and allergic con-comitant symptoms.Method and ResultsI. Experiments on 200 cases with no history of receiving enramycinThe intracutaneous tests were performed on these cases. Vesicle and flare were recognized in 4 cases (2%) and 2 (1. 0%), respectively, as immediate positive reaction. While, as delayed positive reaction occurred flare in 3 cases (1. 5%) and induration in 1 (0. 5%).II. Experiments on 217 cases with a history of enramycin therapy, intramuscularly or topically1) One hundred and seventy-six cases had been tested as to the intracutaneous immediate reaction before the beginning of enramycin therapy. Vesicle occurred in 4 cases (2. 3%) and flare in 3 (1. 7%). While, 188 cases were tested about the same reaction after the end of enramycin therapy. Vesicle occurred in 6 cases (3. 2%) and flare in 4 (2. 1%).2) No significant differences both in the size of intracutaneous reaction and in the number of positive reaction were observed between 176 cases tested before the therapy and 188 cases after the therapy.3) There were 6 cases (vesicle in 3, flare in 3) whose reaction had changed from negative before the therapy to positive after the therapy, and 2 cases (vesicle in one, flare in one) whose reaction had changed from positive to negative.4) When the injectable solution (not diluted) was used as the intracutaneous test solution, a number of false positive cases were noted. They were due to the non-specific reaction induced by the injection.5) Anti-enramycin antibody in blood were examined by PCA reaction test and complement fixation test in 71 cases. As the result, no positive cases were noted except one topically administered case who showed positive PCA reaction probably due to the cross reaction with fungi.6) Concerning allergic concomitant symptoms in 217 cases, 6 cases showed rash or dermatitis during the therapy. These reactions seemed to be stronger in the cases of topical application than in the cases of intramuscular administration.DiscussionAlthough the above results are insufficient to draw a conclusion as to the antigenicity of this antibiotic, it may be said that this drug is not dangerous for a intramuscular administration if topical administration in form of ointment is avoided and adequate care is paid to strongly allergic diathesis and the cases with a history of enramycin therapy or of hypersensitivity to fungi.